{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:30:35Z","timestamp":1792564235769,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jtos.2022.12.009","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:42:49Z","timestamp":1672447369000},"page":"108-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Long term study of topical interferon \u03b1-2b eye drops as primary treatment of ocular surface squamous neoplasia"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8303-1800","authenticated-orcid":false,"given":"Wathanee","family":"Sripawadkul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Reyes-Capo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Zein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Wylegala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Albayyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Galor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-7181","authenticated-orcid":false,"given":"Carol L.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtos.2022.12.009_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0039-6257(05)80054-2","article-title":"Ocular surface squamous neoplasia","volume":"39","author":"Lee","year":"1995","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2022.12.009_bib2","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2004.02.013","article-title":"Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors","volume":"111","author":"Shields","year":"2004","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jtos.2022.12.009_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.survophthal.2003.10.008","article-title":"Tumors of the conjunctiva and cornea","volume":"49","author":"Shields","year":"2004","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"10.1016\/j.jtos.2022.12.009_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237453","article-title":"Observational study of ocular surface squamous neoplasia: risk factors, diagnosis, management and outcomes at a tertiary eye hospital in South Africa","volume":"15","author":"H\u04e7llhumer","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jtos.2022.12.009_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1442-9071.1997.tb01514.x","article-title":"Retrospective study of ocular surface squamous neoplasia","volume":"25","author":"Lee","year":"1997","journal-title":"Aust N Z J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2022.12.009_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0002-9394(84)90371-4","article-title":"Clinical and pathologic description of 17 cases of corneal intraepithelial neoplasia","volume":"97","author":"Waring","year":"1984","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2022.12.009_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0161-6420(86)33764-3","article-title":"Conjunctival and corneal intraepithelial and invasive neoplasia","volume":"93","author":"Erie","year":"1986","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jtos.2022.12.009_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0161-6420(01)00991-5","article-title":"Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia","volume":"109","author":"Scott","year":"2002","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.jtos.2022.12.009_bib9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archopht.1997.01100150810025","article-title":"Surgical management of conjunctival tumors. The 1994 lynn B. McMahan lecture","volume":"115","author":"Shields","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2022.12.009_bib10","first-page":"109","article-title":"Conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes--the 2017 J. Donald M. Gass lecture","volume":"6","author":"Shields","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"3","key":"10.1016\/j.jtos.2022.12.009_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.ico.0000138834.42489.ba","article-title":"Ocular surface squamous neoplasia: a standard of care survey","volume":"24","author":"Stone","year":"2005","journal-title":"Cornea"},{"issue":"12","key":"10.1016\/j.jtos.2022.12.009_bib12","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/ICO.0b013e3182a6ea6c","article-title":"Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012","volume":"32","author":"Adler","year":"2013","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.jtos.2022.12.009_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/ICU.0b013e3283622a13","article-title":"Topical chemotherapy for ocular surface squamous neoplasia","volume":"24","author":"Nanji","year":"2013","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2022.12.009_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/ICO.0000000000001116","article-title":"Retrospective comparative study of topical interferon \u03b12b versus mitomycin C for primary ocular surface squamous neoplasia","volume":"36","author":"Kusumesh","year":"2017","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.jtos.2022.12.009_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ophtha.2013.11.017","article-title":"Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications","volume":"121","author":"Nanji","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.jtos.2022.12.009_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archophthalmol.2011.385","article-title":"Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification","volume":"130","author":"Shah","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.009_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ajo.2018.11.007","article-title":"Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia","volume":"199","author":"Venkateswaran","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2022.12.009_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jir.2018.0125","article-title":"Interferon alpha 2a and 2b in ophthalmology: a review","volume":"39","author":"Lewczuk","year":"2019","journal-title":"J Interferon Cytokine Res"},{"issue":"9","key":"10.1016\/j.jtos.2022.12.009_bib19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archopht.1994.01090210029007","article-title":"Regression of limbal epithelial dysplasia with topical interferon","volume":"112","author":"Maskin","year":"1994","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.jtos.2022.12.009_bib20","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/bjo.2006.107482","article-title":"Ocular surface toxicity associated with topical interferon alpha-2b","volume":"91","author":"Aldave","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.jtos.2022.12.009_bib21","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.ophtha.2010.03.052","article-title":"Subconjunctival\/perilesional recombinant interferon \u03b12b for ocular surface squamous neoplasia: a 10-year review","volume":"117","author":"Karp","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jtos.2022.12.009_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0161-6420(99)90009-X","article-title":"Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia11The authors have no proprietary interest in the development or marketing of any drug mentioned in this article","volume":"106","author":"Vann","year":"1999","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.jtos.2022.12.009_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/APO.0000000000000104","article-title":"Topical interferon \u03b1-2b as a single therapy for primary ocular surface squamous neoplasia","volume":"4","author":"Kusumesh","year":"2015","journal-title":"Asia Pac J Ophthalmol (Phila)."},{"issue":"3","key":"10.1016\/j.jtos.2022.12.009_bib24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/ICO.0b013e3182523f61","article-title":"Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the American Joint Committee on Cancer classification","volume":"32","author":"Shields","year":"2013","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.jtos.2022.12.009_bib25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/2452-2325.329089","article-title":"Recombinant interferon alpha-2b as primary treatment for ocular surface squamous neoplasia","volume":"33","author":"Ghaffari","year":"2021","journal-title":"J Curr Ophthalmol"},{"issue":"7\u20138","key":"10.1016\/j.jtos.2022.12.009_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/08820538.2019.1648691","article-title":"Interferon alfa 2b for ocular surface squamous neoplasia: factors influencing the treatment response","volume":"34","author":"Kaliki","year":"2019","journal-title":"Semin Ophthalmol"},{"issue":"10","key":"10.1016\/j.jtos.2022.12.009_bib27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4103\/0301-4738.195010","article-title":"Recombinant interferon alpha 2b for ocular surface squamous neoplasia: an efficient and cost-effective treatment modality in Asian Indian patients","volume":"64","author":"Kaliki","year":"2016","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2022.12.009_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/ojo.OJO_201_2018","article-title":"Treatment outcome with interferon alpha 2b in ocular surface squamous neoplasia: recommendation as primary treatment by peripheral ophthalmologists","volume":"14","author":"Meel","year":"2021","journal-title":"Oman J Ophthalmol"},{"issue":"8","key":"10.1016\/j.jtos.2022.12.009_bib29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.ophtha.2007.10.039","article-title":"Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b","volume":"115","author":"Schechter","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jtos.2022.12.009_bib30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4103\/ijo.IJO_1665_20","article-title":"Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: comparative analysis of outcomes based on original tumor configuration","volume":"69","author":"Shields","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.009_bib31","series-title":"AJCC cancer staging manual","first-page":"1032","year":"2017"},{"issue":"11","key":"10.1016\/j.jtos.2022.12.009_bib32","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/ICO.0000000000002615","article-title":"Ocular surface squamous neoplasia managed with primary interferon \u03b12b: a comparative analysis of 212 tumors in smokers versus nonsmokers","volume":"40","author":"Shields","year":"2021","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.jtos.2022.12.009_bib33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0000000000002350","article-title":"Interferon alfa-2b for pigmented ocular surface squamous neoplasia: a report of 8 lesions","volume":"40","author":"Kaliki","year":"2021","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jtos.2022.12.009_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003226-200201000-00003","article-title":"Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b","volume":"21","author":"Schechter","year":"2002","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.jtos.2022.12.009_bib35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jtos.2020.04.004","article-title":"The treatment of recurrent conjunctival and corneal intraepithelial neoplasia with interferon alfa-2b and retinoic acid: \u223c9 years' follow-up on tumor control","volume":"18","author":"Ip","year":"2020","journal-title":"Ocul Surf"},{"issue":"2","key":"10.1016\/j.jtos.2022.12.009_bib36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/09273948.2017.1394470","article-title":"Challenging treatment of ocular surface squamous neoplasia in patients with atopic disease","volume":"27","author":"Zhang","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.jtos.2022.12.009_bib37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/bjo.2008.153197","article-title":"Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study","volume":"94","author":"Galor","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2022.12.009_bib38","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/ICO.0000000000001153","article-title":"Immunosuppression as a possible risk factor for interferon nonresponse in ocular surface squamous neoplasia","volume":"36","author":"Ashkenazy","year":"2017","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.jtos.2022.12.009_bib39","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.jtos.2022.12.009_bib40","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ophtha.2016.02.034","article-title":"Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia","volume":"123","author":"Joag","year":"2016","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.jtos.2022.12.009_bib41","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/bjophthalmol-2016-309219","article-title":"Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study","volume":"101","author":"Parrozzani","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.009_bib42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40662-019-0150-5","article-title":"Update on pharmacotherapy for ocular surface squamous neoplasia","volume":"6","author":"Al Bayyat","year":"2019","journal-title":"Eye Vis (Lond)."}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012422001264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012422001264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T18:47:51Z","timestamp":1716403671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012422001264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":42,"alternative-id":["S1542012422001264"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2022.12.009","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long term study of topical interferon \u03b1-2b eye drops as primary treatment of ocular surface squamous neoplasia","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2022.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}